Summary of Significant Accounting Policies (Details 2)	9 Months Ended	3 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012 Supplier concentration item	Dec. 31, 2011 Accounts receivable Accounts receivable balances Forest Laboratories, Inc.	Sep. 30, 2012 Accounts receivable Accounts receivable balances Almirall, S.A.	Dec. 31, 2011 Accounts receivable Accounts receivable balances Almirall, S.A.	Sep. 30, 2012 Accounts receivable Accounts receivable balances Astellas Pharma Inc.	Dec. 31, 2011 Accounts receivable Accounts receivable balances Astellas Pharma Inc.	Sep. 30, 2012 Revenue Forest Laboratories, Inc.	Sep. 30, 2011 Revenue Forest Laboratories, Inc.	Sep. 30, 2012 Revenue Forest Laboratories, Inc.	Sep. 30, 2011 Revenue Forest Laboratories, Inc.	Sep. 30, 2012 Revenue Almirall, S.A.	Sep. 30, 2011 Revenue Almirall, S.A.	Sep. 30, 2012 Revenue Almirall, S.A.	Sep. 30, 2011 Revenue Almirall, S.A.	Sep. 30, 2012 Revenue Astellas Pharma Inc.	Sep. 30, 2011 Revenue Astellas Pharma Inc.	Sep. 30, 2012 Revenue Astellas Pharma Inc.	Sep. 30, 2011 Revenue Astellas Pharma Inc.
Revenue and accounts receivable by major customer; third-party manufacturers
Revenue and accounts receivable by major customer (as a percent)			86.00%	7.00%	2.00%	93.00%	11.00%	93.00%	45.00%	82.00%	49.00%	6.00%	48.00%	16.00%	43.00%	1.00%	7.00%	2.00%	8.00%
Number of third-party manufacturers		2
Number of manufacturing facilities		3
Percentage of net profit from commercialization	50.00%
Percentage of net loss from commercialization	50.00%